Fulvestrant Powder Pharmaceutical Raw Materials Drugs for Breast Cancer

» pharmazeutisch » Anti-Tumor-Medikamente » Fulvestrant Powder Pharmaceutical Raw Materials Drugs for Breast Cancer

  • Spezifikationen

Buy Fulvestrant Powder Selective Estrogen Receptor Degrader Drug for Breast Cancer Online

 

Fulvestrant Specification

Product Name: Fulvestrant
CAS: 129453-61-8
Standard: USP35
Natural/Synthetic: Synthetic
Level: Pharmaceutical grade
Content: 99%
Aussehen: white powder
Packing: 10G/Aluminum foil bag
Category: Pharmazeutische Rohstoffe
Industry: Pharmaceuticals
Field: Steroid anti-estrogen drugs
Deferred product: Fulvestrant injection
Use: Estrogen receptor-positive locally advanced or metastatic mammary glands that can be used after anti-estrogen adjuvant therapy or during treatment, or after menopause (including natural menopause and artificial menopause) in anti-estrogen therapy cancer.
Usage and dosage: 1. Adult females (including elderly women): The recommended dose is once a month, once 250mg. There is a lack of information on the safety and efficacy of Chinese patients at higher doses. 2. Children and Adolescents: Since the safety and effectiveness of this product in children and adolescents have not been determined, the use of this product in this age group is not recommended. 3. Patients with impaired renal function: For patients with mild-to-moderate renal impairment (creatinine clearance ≥ 30 ml/min), there is no need to adjust the dose.

 

What is Fulvestrant?

Fulvestrant is a medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.

Fulvestrant is given by injection into a muscle.

 

Fulvestrant Certificate of Analysis

Produktname Fulvestrant
CAS-Nr. 129453-61-8 äußere Verpackung 10g/foil bag
Produktionsdatum 2017-10-22 Haltbarkeit 2019-10-18
Standard, der USP35
Elemente der Analyse Spezifikation Ergebnisse
Aussehen A white to off-white crystalline powder Konform
Identifizierung 1、IR IR should conform to the standard Konform
Specific rotaion +108°~ +115° 110.8°
6-Keto Fulvestran ≤0.1% 0.05%
∆6,7-Fulvestran ≤0.1% 0.08%
Fulvestrant sulfone ≤0.2% 0.11%
Fulvestrant extended ≤0.3% 0.08%
Fulvestrant sterol dimmer ≤0.8% 0.09%
Fulvestrant β-isomer ≤0.1% 0.06%
Any individual unspecified impurity ≤0.1% 0.03%
Total impurity ≤1.0% 0.7%
FulvestrantA 42%~48% 45.42%
FulvestrantB 52%~58% 54.58%
Rückstand auf lgnition ≤0.1% 0.03%
Drying loss ≤0.5 % 0.30%
Water ≤0.5 % 0.26%
Probe 98.0%~102% 99.2%
Schlussfolgerung Qualifizierte

 

Fulvestrant Side Effects

Very common (occurring in more than 10% of people) adverse effects include nausea, injection site reactions, weakness, and elevated transaminases. Common (between 1% und 10%) adverse effects include urinary tract infections, hypersensitivity reactions, loss of appetite, headache, blood clots in veins, hot flushes, vomiting, diarrhea, elevated bilirubin, rashes, and back pain.

Sales Contacts

Tel/Whatsapp: +86 17707567122
Wickr: mollyying
Telegramm: +86 185785209851
Skype: ying_2073
Mail: ying@wumeitech.com

Anfrageformular ( wir werden wieder so schnell wie möglich erhalten )

Name:
*
Email:
*
Botschaft:

Nachprüfung:
5 + 9 = ?

Vielleicht gefällt Ihnen auch

  • Produktkategorien

  • kürzliche Posts

  • Aktie

  • Kontaktiere uns

    E-Mail: ying@wumeitech.com
    Tel: 86-0756-8811069
    Fax: 86-0756-8811095
    Tel / whatsapp: +86 17707567122
    Wicker ID: molly160529
    Telegramm: +86 17707567122